Trial Profile
A multicenter, single-arm, open-label, study to evaluate the safety and efficacy of single-agent lenalidomide [Revlimid®] in subjects with androgen independent prostate cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 Jul 2006 Status change
- 22 Oct 2005 New trial record.